Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s DiseaseBrodaty H. · Corey-Bloom J. · Potocnik F.C.V. · Truyen L. · Gold M. · Damaraju C.R.V.
aUniversity of New South Wales, Sydney, Australia; bUniversity of California, San Diego, Calif., USA; cStikland Hospital, Bellville, South Africa; dJohnson & Johnson Pharmaceutical Research and Development, Titusville, N.J., USA
The primary objective of this study was to evaluate the efficacy and tolerability of a flexible dosing regimen (16 or 24 mg/day) of galantamine prolonged-release capsule (PRC) compared with placebo in subjects with mild to moderate Alzheimer’s disease (AD). This phase III, double-blind, placebo- and active-controlled, parallel-group trial randomized 971 patients to treatment for 6 months. Efficacy endpoints included change in the 11-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog/11), Clinician’s Interview-Based Impression of Change plus caregiver input (CIBIC-plus), Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), and Neuropsychiatric Inventory (NPI) scores. Galantamine was associated with significant improvements in the ADAS-cog/11 score but not in the CIBIC-plus or NPI scores. Galantamine PRC was associated with significant improvement in ADCS-ADL scores. Galantamine PRC had similar tolerability and safety profiles compared with twice-daily galantamine, and when administered as a once-daily flexible dosing regimen of 16 or 24 mg/day, was demonstrated to be as safe and effective for the treatment of mild to moderate AD.